References

Amenorrhea

  1. 1.Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea: a committee opinion. Fertil Steril. 2024;122(1):52-61.
  2. 2.Solnik MJ. Evaluation of primary amenorrhea. BMJ Best Practice. Updated August 11, 2026. Accessed October 1, 2026. https://bestpractice.bmj.com/topics/en-us/1101​
  3. 3.Klein DA, Paradise SL, Reeder RM. Amenorrhea: a systematic approach to diagnosis and management. Am Fam Physician. 2019;100(1):39-48.
  4. 4.Fowler LR, Gillard C, Morain SR. Readability and accessibility of terms of service and privacy policies for menstruation-tracking smartphone applications. Health Promot Pract. 2020;21(5):679-683.
  5. 5.Mohan S, Jenkins J. Flowing data: women’s views and experiences on privacy and data security when using menstrual cycle tracking apps. Oxf Open Digit Health. 2025;3:oqaf011.
  6. 6.Logue DM, Madigan SM, Melin A, et al. Low energy availability in athletes 2020: an updated narrative review of prevalence, risk, within-day energy balance, knowledge, and impact on sports performance. Nutrients. 2020;12(3):835.
  7. 7.Centers for Disease Control and Prevention. Contraception. Injectables. November 19, 2024. Accessed July 21, 2026. https://www.cdc.gov/contraception/hcp/usspr/injectables.html​
  8. 8.Osoti A, Kidula N, Mengesa LB, et al. Return to fertility after subcutaneous depot medroxyprogesterone acetate: a narrative review. BMJ Sex Reprod Health. 2025;51:s52-s59.
  9. 9.Sergison JE, Maldonado LY, Gao X, et al. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis. Am J Obstet Gynecol. 2019;220(5):440-448.e8.
  10. 10.Centers for Disease Control and Prevention. Intrauterine contraception. November 19, 2024. Accessed July 21, 2026. https://www.cdc.gov/contraception/hcp/usspr/intrauterine-contraception.html​
  11. 11.Curtis KM, Nguyen AT, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2024. MMWR Recomm Rep. 2024;73(3):1-77.
  12. 12.Stuenkel CA, Gompel A. Primary ovarian insufficiency. N Engl J Med. 2023;388(2):154-163.
  13. 13.Yatsenko SA, Witchel SF, Gordon CM. Primary amenorrhea and premature ovarian insufficiency. Endocrinol Metab Clin North Am. 2024;53(2):293-305.
  14. 14.Teede HJ, Tay CT, Laven JJE, et al.; International PCOS Network. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-G64.
  15. 15.American Society for Reproductive Medicine. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome. October 2023. Accessed July 21, 2026. https://www.asrm.org/practice-guidance/practice-committee-documents/recommendations-from-the-2023-international-evidence-based-guideline-for-the-assessment-and-management-of-polyendocrine-metabolic-ovarian-syndrome-2023/​
  16. 16.Kalsi AK, Halder A, Jain M, et al. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019;63(2):332-340.
  17. 17.Samson SL, Hamrahian AH, Ezzat S; Neuroendocrine AACE and Pituitary Scientific Committee. American College of Endocrinology (ACE). American Association of Clinical Endocrinologists, American College of Endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract. 2015;21(12):1427-1435.
  18. 18.Stuenkel CA. Cynthia Stuenkel, MD, talks evaluating and managing primary ovarian insufficiency. Contemporary OB/GYN. October 24, 2025. Accessed July 21, 2026. https://www.contemporaryobgyn.net/view/cynthia-stuenkel-md-talks-evaluating-and-managing-primary-ovarian-insufficiency​
  19. 19.Teede HJ, Khomami MB, Morman R, et al.; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339.
  20. 20.Christianson MS, King JA, Zacur HA. Clinical Gynecology. ChristiansonMSKingJAZacurHA. Hyperprolactinemia. In: BieberEJSanfilippoJSHorowitzIRet al., eds. Clinical Gynecology. Cambridge University Press; 2015:929-941.
  21. 21.Wong L, Leibner L, Vicioso C, et al. Functional hypothalamic amenorrhea in adolescent athletes impairs bone accrual and increases fracture risk. Front Endocrinol (Lausanne). 2025;16:1709695.
  22. 22.Meczekalski B, Niwczyk O, Bala G, et al. Managing early onset osteoporosis: the impact of premature ovarian insufficiency on bone health. J Clin Med. 2023;12(12):4042.
  23. 23.Tay CT, Mousa A, Vyas A, et al. 2023 international evidence-based polycystic ovary syndrome guideline update: insights from a systematic review and meta-analysis on elevated clinical cardiovascular disease in polycystic ovary syndrome. J Am Heart Assoc. 2024;13(16):e033572.
  1. 1.ACOG Committee Opinion No. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891-896.
  2. 2.Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393-408.
  3. 3.Selander-Han M, McGee S, Lo K. Female reproductive endocrine disorders. Prim Care. 2024;51(3):431-443.
  4. 4.Wouk N, Helton M. Abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2019;99(7):435-443.
  5. 5.National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. March 14, 2018. Updated July 7, 2026. Accessed August 18, 2026. https://www.nice.org.uk/guidance/ng88/resources​
  6. 6.Jain V, Munro MG, Critchley HOD. Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO systems 1 and 2. Int J Gynaecol Obstet. 2023;162:29-42.
  7. 7.Zhimei Liu, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183-194.
  8. 8.Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012;120(1):197-206
  9. 9.Pegu B, Srinivas BH, Saranya TS, et al. Cervical polyp: evaluating the need of routine surgical intervention and its correlation with cervical smear cytology and endometrial pathology: a retrospective study. Obstet Gynecol Sci. 2020;63(6):735-742.
  10. 10.Marnach ML, Laughlin-Tommaso SK. Evaluation and management of abnormal uterine bleeding. Mayo Clin Proc. 2019;94(2):326-335.
  11. 11.Papakonstantinou E, Adonakis G. Management of pre-, peri-, and post-menopausal abnormal uterine bleeding: when to perform endometrial sampling? Int J Gynaecol Obstet. 2022;158(2):252-259.
  12. 12.Stewart EA, Laughlin-Tommaso SK. Uterine fibroids. N Engl J Med. 2024;391(18):1721-1733.
  13. 13.National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: uterine cancer. Accessed October 23, 2026. https://seer.cancer.gov/statfacts/html/corp.html​
  14. 14.Byar KL, Fredericks T. Uterine leiomyosarcoma. J Adv Pract Oncol. 2022;13(1):70-76.
  15. 15.Paruchuri B, Miller A. Gynecologic cancers: cervical cancer. FP Essent. 2025;558:6-14.
  16. 16.Côté M, Genest C, Richard E, et al. Evaluation of a standardized questionnaire for initial assessment of abnormal uterine bleeding in premenopausal women. J Obstet Gynaecol Can. 2022;44(11):1136-1142.
  17. 17.Centers for Disease Control and Prevention. Data and statistics on Von Willebrand disease. May 14, 2024. Accessed March 2, 2026. https://www.cdc.gov/ncbddd/vwd/data.html​
  18. 18.International Society on Thrombosis and Haemostasis Scientific and Standardization Committee. Bleeding Score and Bleeding Questionnaire for the Diagnosis of Type 1 von Willebrand Disease. Accessed May 18, 2026. https://www.isth.org/resource/resmgr/ssc/bleeding_type1_vwd.pdf​
  19. 19.Robbins JB, Sadowski EA, Maturen KE, et al.; Expert Panel on GYN and OB Imaging. ACR Appropriateness Criteria® abnormal uterine bleeding. J Am Coll Radiol. 2020;17(11):S336-S345.
  20. 20.Schrager S, Fox K, Lee R. Abnormal uterine bleeding associated with hormonal contraception. Am Fam Physician. 2024;109(2):161-166.
  21. 21.Alves RDMS, Rabelo MM, Andrade VR, et al. The influence of the levonorgestrel-releasing intrauterine system position on bleeding patterns in reproductive age women. Int J Gynaecol Obstet. 2019;147(3):326-331.
  22. 22.Upawi SN, Ahmad MF, Abu MA, et al. Management of bleeding irregularities among etonogestrel implant users: is combined oral contraceptives pills or nonsteroidal anti-inflammatory drugs the better option?. J Obstet Gynaecol Res. 2020;46(3):479-484.
  23. 23.Teede HJ, Misso ML, Costello MF, et al.; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364-379.
  24. 24.American College of Obstetricians & Gynecologists. Updated guidance regarding the role of transvaginal ultrasonography in evaluating the endometrium of individuals with postmenopausal bleeding. Obstet Gynecol. 2026;148(1):e87-e91.
  25. 25.Black D. Diagnosis and medical management of abnormal premenopausal and postmenopausal bleeding. Climacteric. 2023;26(3):222-228.
  26. 26.Creinin MD, Barnhart KT, Gawron LM, et al. Heavy menstrual bleeding treatment with a levonorgestrel 52-mg intrauterine device. Obstet Gynecol. 2023;141(5):971-978.
  27. 27.Bryant-Smith AC, Lethaby A, Farquhar C, et al. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2018(4):CD000249.
  28. 28.Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2016;2016(1):CD003855.
  29. 29.Cetin F, Kayar İ, Birge Ö, et al. Malignancy risk factors based on endometrial polyp. BMC Womens Health. 2024;24(1):567.
  30. 30.Middelkoop MA, Don EE, Hehenkamp WJK, et al. Angiogenesis in abnormal uterine bleeding: a narrative review. Hum Reprod Update. 2023;29(4):457-485.
  31. 31.ACOG Committee Opinion No. 774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. Obstet Gynecol. 2019;133(4):e279-e284.
  32. 32.Kayhan F, Alptekin H, Kayhan A. Mood and anxiety disorders in patients with abnormal uterine bleeding. Eur J Obstet Gynecol Reprod Biol. 2016;199:192-197.
  1. 1.Marnach ML, Laughlin-Tommaso SK. Evaluation and management of abnormal uterine bleeding. Mayo Clin Proc. 2019;94(2):326-335.
  2. 2.Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(9):1210-1222.
  3. 3.Carugno J. Clinical management of vaginal bleeding in postmenopausal women. Climacteric. 2020;23(4):343-349.
  4. 4.American College of Obstetricians & Gynecologists. Updated guidance regarding the role of transvaginal ultrasonography in evaluating the endometrium of individuals with postmenopausal bleeding. Obstet Gynecol. 2026;148(1):e87-e91.
  5. 5.Jo HC, Baek JC, Park JE, et al. Clinicopathologic characteristics and causes of postmenopausal bleeding in older patients. Ann Geriatr Med Res. 2018;22(4):189-193.
  6. 6.Santoro N, Roeca C, Peters BA, et al. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021;106(1):1-15.
  7. 7.Ring KL, Mills AM, Modesitt SC. Endometrial hyperplasia. Obstet Gynecol. 2022;140(6):1061-1075.
  8. 8.Practice Bulletin No. 149: endometrial cancer. Obstet Gynecol. 2015;125(4):1006-1026.
  9. 9.Labrie F, Archer DF, Koltun W, et al.; VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-256.
  10. 10.Cooper JM, Brady RM. Hysteroscopy in the management of abnormal uterine bleeding. Obstet Gynecol Clin North Am. 1999;26(1):217-236.
  1. 1.Ferries-Rowe E, Corey E, Archer JS. Primary dysmenorrhea: diagnosis and therapy. Obstet Gynecol. 2020;136(5):1047-1058.
  2. 2.Amza M, Findeklee S, Haj Hamoud B, et al. Dysmenorrhea and its impact on patients’ quality of life–a cross-sectional study. J Clin Med. 2024;13(19):5660.
  3. 3.Ishikura IA, Hachul H, Tufik S, et al. Dysmenorrhea and sleep: a review. Sleep Med Clin. 2023;18(4):449-461.
  4. 4.Schoep ME, Nieboer TE, van der Zanden M, et al. The impact of menstrual symptoms on everyday life: a survey among 42,879 women. Am J Obstet Gynecol. 2019;220(6):569.e1-569.e7.
  5. 5.Sawyer G, Fraser A, Lawlor DA, et al. Associations of adolescent menstrual symptoms with school absences and educational attainment: analysis of a prospective cohort study. NPJ Sci Learn. 2025;10(1):54.
  6. 6.ACOG Committee Opinion No. 760: dysmenorrhea and endometriosis in the adolescent. Obstet Gynecol. 2018;132(6):e249-e258.
  7. 7.Gutman G, Nunez AT, Fisher M. Dysmenorrhea in adolescents. Curr Probl Pediatr Adolesc Health Care. 2022;52(5):101186.
  8. 8.Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. 2006;332(7550):1134-1138.
  9. 9.Burnett M. Guideline No. 345: primary dysmenorrhea. J Obstet Gynaecol Can. 2025;47(5):102840.
  10. 10.Jenabi E, Khazaei S, Veisani Y. The relationship between smoking and dysmenorrhea: a meta-analysis. Women Health. 2019;59(5):524-533.
  11. 11.McKenna KA, Fogleman CD. Dysmenorrhea. Am Fam Physician. 2021;104(2):164-170.
  12. 12.Guimarães I, Póvoa AM. Primary dysmenorrhea: assessment and treatment. Rev Bras Ginecol Obstet. 2020;42(8):501-507.
  13. 13.Marjoribanks J, Ayeleke RO, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015(7):CD001751.
  14. 14.US Food and Drug Administration. Depo-Provera CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use. Prescribing information. December 2025. Accessed May 18, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020246s074lbl021583s045lbl.pdf​
  15. 15.Carrubba AR, Ebbert JO, Spaulding AC, et al. Use of cannabis for self-management of chronic pelvic pain. J Womens Health (Larchmt). 2021;30(9):1344-1351.
  16. 16.Moya RA, Moisa CF, Morales F, et al. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet. 2000;69(2):113-118.
  17. 17.Centers for Disease Control and Prevention. Summary chart of U.S. medical eligibility criteria for contraceptive use (U.S. MEC). July 2024. Accessed May 18, 2026. https://www.cdc.gov/contraception/media/pdfs/2024/07/us-mec-summary-chart-color-508.pdf​
  18. 18.Schroll JB, Black AY, Farquhar C, et al. Combined oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev. 2023(7):CD002120.
  19. 19.US Food and Drug Administration. Depo-subQ Provera 104® medroxyprogesterone acetate injectable suspension, 104 mg/0.65 mL. Prescribing information. November 2016. Accessed May 18, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021583s031lbl.pdf​
  20. 20.US Food and Drug Administration. Nexplanon (etonogestrel implant). Prescribing information. December 2018. Accessed May 18, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021529s018lbl.pdf​
  21. 21.Li Y, Li D, Feng T, et al. Clinical efficacy of etonogestrel implants on relieving dysmenorrhea in endometriosis and adenomyosis women for up to 3 years. Front Med (Lausanne). 2025;12:1460578.
  22. 22.Bayer HealthCare Pharmaceuticals Inc. Mirena (levonorgestrel-releasing intrauterine system). Prescribing information. July 2024. Accessed May 18, 2026 https://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf​
  23. 23.Armour M, Ee CC, Naidoo D, et al. Exercise for dysmenorrhoea. Cochrane Database Syst Rev. 2019(9):CD004142.
  24. 24.Yaralizadeh M, Nezamivand-Chegini S, Najar S, et al. Effectiveness of magnesium on menstrual symptoms among dysmenorrheal college students: a randomized controlled trial. Int J Women’s Health Reprod Sci. 2024;12(2):70-76.
  25. 25.Kirsch E, Rahman S, Kerolus K, et al. Dysmenorrhea, a narrative review of therapeutic options. J Pain Res. 2024;17:2657-2666.
  26. 26.Liu J, Wang Y, Zhang J, et al. Efficacy and safety of non-pharmacological therapies for primary dysmenorrhea: a network meta-analysis. J Pain Res. 2025;18:975-991.
  27. 27.Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28-40.
  28. 28.Rogers SK, Ahamadeen N, Chen CX, et al. Dysmenorrhea and psychological distress: a meta-analysis. Arch Womens Ment Health. 2023;26(6):719-735.
  29. 29.Jarrell J, Arendt-Nielsen L. Allodynia and dysmenorrhea. J Obstet Gynaecol Can. 2016;38(3):270-274.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.